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Abstract 
AIM: To assess the risk factor for diabetic atherosclerosis nephropathy and diabetic nephropathy in type 1 
diabetic patients. 
PATIENTS AND METHODS: Thirty healthy volunteers age and sex-matched and Sixty-five type 1 diabetic patient 
were in rolled in the study. The mean age of patients was 17.99 ± 2.59 years, mean age of onset of diabetes was 
7.00 ± 3.28 years, mean duration of diabetes was 10.91 ± 3.54 years. Glycosylated sex-matched (HbA1c) was 
assessed in blood samples, serum lipid profile was determined, and serum level of oxidised low-density 
lipoprotein (OxLDL), and nitric oxide was evaluated by enzyme-linked immunosorbent assay (ELISA) technique. 
Nitric oxide 894G > T genotype was analysed by (PCR-RFLP) method and confirmed by Sequencing. 
Assessment of the albumin / creatinine ratio was done in urine samples. Renal Doppler and Carotid intima-media 
thickness (cIMT) via ultrasound was also performed. 
RESULTS: OxLDL, lipid profile, albumin/creatinine ratio, cIMT and resistivity index were significantly higher in 
diabetic patients while nitric oxide was significantly lower. Nitric oxide genotype shows no significant difference 
between diabetic’s patients and controls. Diabetic patients with homozygous NO had a significantly lower serum 
level of Nitric oxide, a significantly higher OxLDL, albumin / creatinine ratio and lipid profile. 
CONCLUSION: diabetic patients are liable for the occurrence of early diabetic nephropathy and atherosclerosis 
as a result of the presence of low level of nitric oxide. Nitric oxide gene polymorphism 894G > T in diabetic 
patients is a risk factor for diabetic nephropathy and atherosclerosis. 
 
 
Introduction 
 
Several Pathophysiological changes that lead 
to diabetic nephropathy are triggered by oxidative 
stress, advanced glycation end products and 
hypertension [1], [2]. Suppression of vascular 
dilatation factors with a subsequent reduction in the 
release or production of Endothelium-derived relaxing 
factor (EDRF) contribute to the initiation and 
augmentation of diabetic nephropathy. Decrease the 
production of nitrous oxide (NO) that is released by 
vascular endothelium as a vasodilatation factor also 
have a role in this regard. Reduction in nitrous oxide 
synthase (NOS) production may cause a decrease in 
NO level and vascular dilatation [3]. The enzyme 
Endothelial nitrous oxide synthetase (ENOS) is 
important for the contribution of vascular homeostasis 
and eNOS gene has 26 exons and is located on 
chromosome 7 [4], [5]. 
Angiotensin-Converting Enzyme gene 
polymorphism plays a pivotal role in diabetic 
nephropathy [6]. DD allele of the ACE gene has a role 
in the development and affect the severity of diabetic 
nephropathy with more rapid progression to end-stage 
renal disease [7]. For example, a positive association 
has been exemplified between proteinuria, and the D 
allele of ACE Polymorphism in a study enrolled 109 
types 2 diabetic patients [8]. As there is a 
disagreement in the results of studies, some studies 
with large sample size done on specific races could 
not find this correlation [9]. In other studies, the 
correlation between diabetic nephropathy and its 
severity and polymorphism of some alleles of the 
eNOS gene are reported [10], [11], [12]. 
We are aiming to evaluate the risk factor for 
diabetic nephropathy and early atherosclerosis in type 
1 diabetic patients. 
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Patients and Methods 
 
Patients 
The study included 65 adolescent type 1 
diabetics among those attending to the endocrine 
clinic, Medical Center of Excellence, National 
Research Centre. The control group consisted of 30 
healthy normal volunteers with age and sex-matched. 
Control group was the healthy friends or relatives of 
our patients. 
Children with type 1 DM, duration of disease > 
5 years, patients age > 14 and < 19 yrs old were 
included in the study. We selected this age group of 
patients with short duration of diabetes, firstly, to 
explore whether early atherosclerotic changes start in 
short duration of diabetes or needs longer exposure to 
the diabetic milieu and secondly because in younger 
age group (< 14 yrs old) atherosclerotic lesions are 
expected to be in the form of microscopic intimal fatty 
streaks that is too minute to be resolved by 
ultrasonography. 
Patients during acute diabetic complications, 
e.g. diabetic ketoacidosis (DKA) or hypoglycemia, 
patients suffering from cardiac diseases, e.g. 
congenital, rheumatic heart, left ventricular 
dysfunction, patients on metformin or multivitamins 
and smokers were excluded from the study.  
 
Study design and protocol 
It is a cross-sectional observational study 
done after obtaining approval from the ethical 
committee of the National Research Centre, Cairo, 
Egypt. The registration number is 11052. Written 
informed consent was obtained from all patients or 
their parents and controls after the full discussion 
about the aim of the study. This study is a part of a 
project done in the National Research Centre for 
evaluation of cardiac, vascular and endothelial 
function in adolescent type 1 diabetic patients. 
All the studied patients were subjected to: 
History taking include: age of patients, sex, age of 
onset of diabetes, duration of diabetes, type and dose 
of insulin therapy, family history of diabetes, presence 
of any symptoms of cardiac, renal, neurological 
affection or presence of any autonomic dysfunction 
and history of taking drugs other than insulin.  
 
Clinical examination 
I. Patients and controls were subjected to 
general, cardiac, chest and neurological examination. 
II. Blood pressure was measured three times 
for patients and controls after 5-minute rest in the 
sitting position on both upper limbs with the use of 
automatic manometer (Omron M4 Plus, Omron Health 
care Europe, Hoof drop, and Holland). The mean 
value of the second and the third measurement was 
calculated. The measurements taken on the dominant 
limb were analysed. 
III. Anthropometric measurements in the form 
of weight, height, waist circumference (WC), and hip 
circumference (HC) were taken for each participant. 
The weight and height of the participants were 
measured up to 0.01 kg and 0.1 cm using a Seca 
Scale Standing Balance and a Holtain Portable 
Anthropometer (Holtain, Ltd, Crymych, Wales, U.K.). 
Body mass index (BMI) was calculated as weight (in 
kilograms) divided by height (in meters) squared. 
Waist circumference was measured at the level of the 
umbilicus with the participant standing and breathing 
normally; hip circumference was measured at the 
level of the iliac crest, using non-stretchable plastic 
tape to the nearest 0.1 cm. The waist / hip ratio and 
waist / height ratio (cm / cm) were calculated. Each 
measurement was taken as the mean of three 
consecutive measurements, using standardised 
equipment [13], [14]. The landmarks, instruments 
used, and techniques followed were those 
recommended by the international biological program 
[13], [14]. 
 
Laboratory investigation 
All patients and controls underwent the 
following tests: For cholesterol measurements, 
venous blood was sampled after a 12 h fast. Serum 
total cholesterol was determined by a commercial kit 
(Boehringer-Mannheim, Germany) [15]. High-density 
lipoprotein (HDL) cholesterol was separated from the 
serum by precipitation of the other lipoproteins with a 
heparin / manganese procedure [16]. Low-density 
lipoprotein (LDL) cholesterol was calculated using the 
Friedewald equation. The concentration of 
triglycerides (Tg) was measured in a TechnoCon 
AutoAnalyzer II (TechnoCon Instruments, Tarrytown, 
NY, USA). Glycosylated haemoglobin (HbA1c) was 
done every 3 months, and the mean value was 
calculated per year. It was measured using high-
pressure liquid chromatography (Nichols Institute, Van 
Nuys, CA, USA) [17]. 
Screening for microalbuminuria was assessed 
in fresh morning urine samples by measuring 
albumin/creatinine ratio by enzyme-linked 
immunosorbent assay (ELISA) kit provided by 
Orgentec Diagnostika, Gmbh (Mainz, Germany) [18]. 
Nitric oxide production in sera was measured 
using enzyme-linked immunosorbent assay (ELISA) 
using a kit from Quantikine; R & D Systems, 
Minneapolis; USA. The assay was conducted as per 
the manufacturer’s instructions using NO control with 
a standard curve plotted, and samples were 
measured at a 450 nm wavelength. 
Serum concentrations of oxidised low-density 
lipoprotein (OxLDL) were detected by commercially 
available solid-phase two-site enzyme immunoassay 
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kit (Mercodia AB, Uppsala, Sweden). Measurements 
of the OxLDL levels in the sera were performed 
according to the recommendations of the 
manufacturer. The intra and interassay coefficients of 
variations were 5.5% – 7.3% and 4.0% – 6.2%, 
respectively, and the sensitivity was < 1 mU/L. 
 
Analysis of Nitric oxide G894T SNP by 
 RFLP 
DNA Extraction: Three ml of blood was 
collected from each subject in a sterile EDTA 
vacutainer. Samples were stored at -20°C till DNA 
extraction. Genomic DNA was extracted using the 
QIAamp DNA Mini isolation kit (QIAGEN, # 51304) 
following the manufacturer’s instructions and was 
stored at -20°C until the analysis. The DNA 
concentration was determined at a 260 / 280 nm 
absorbance ratio by NanoDrop 2000c 
Spectrophotometer (Thermo Fisher). 
 
PCR Analysis of G894T SNP 
Genomic DNA was amplified for 
determination of the eNOS G894T SNP using 
polymerase chain reaction (PCR), in a 25 μl reaction 
mixture containing 150 ng genomic DNA, 12.5 μL 
master mix ( QIAGEN, Germany), 5 pmol each 
forward and reverse primers : forward primer 5_TCC 
CTG AGG GCA TGAGGC T-3 and reverse primer 
5_TGA GGGTCA CAC AGG TTC CT-3_ (QIAGEN, 
Germany). DNA was initially denatured at 95°C for 5 
min before amplification. PCR amplification was 
accomplished using 30cycles, consisting of 2 min 
denaturation at 95°C, 45-sec annealing at 62°C, and 1 
min extension at 72°C and the final extension included 
a 1min extension at 72°C. The reaction was carried 
out in BioRad thermal cycler. 
 
Restriction Enzyme Analysis 
The amplified product (10 μl) was digested in 
a 20 μl final reaction volume using 2 μl of Reaction 
Buffer, 8 U of BanII restriction enzyme (Life 
Technologies, USA), samples were then incubated for 
5 hrs at 37°C, digested PCR products were separated 
by 1.2% agarose gel electrophoresis and visualized 
after ethidium bromide staining by UV 
spectrophotometry (Biometra). 
 
Confirmation of PCR by Direct DNA  
  Sequencing 
PCR amplified fragments were completely 
sequenced in both directions using primers and a 
BigDye Terminator Cycler Sequencing Kit v1.1 
(Applied Biosystems, Warrington, UK), reactions were 
analysed on 3100 Genetic Analyzer capillary 
sequencer (Applied Biosystems). Sequences were 
compared using BLAST [Basic Local Alignment 
Search Tool] (www.ncbi.nlm.nih.gov). 
 
Carotid intima-media thickness (cIMT) 
  assessment 
A single experienced vascular sonographer, 
who was blind to the clinical and laboratory data of the 
study subjects, performed all imaging studies. The 
images were obtained using (General Electric medical 
ultrasonographic machine model: Vivid 7 Pro, GE 
Vingmed ultrasound AS-Nl90, Horton-Norway 
equipped with 7.5-10 MHz linear-array transducers). 
Imaging of the carotid arteries is performed in the 
cardiovascular ultrasound laboratory with the subject 
resting in the supine position with his / her neck 
extended, and the head turned 45° toward the 
contralateral side. Care was taken to have the vessel 
as perpendicular as possible to the plane of 
ultrasound beam to ensure optimal imaging of the 
vessel wall in its longitudinal axis with the least 
possible pressure in order not to compress the 
overlying jugular vein and to allow expansion of the 
carotid artery in all directions. A longitudinal section of 
the common carotid artery 1 cm proximal to the 
carotid bulb was imaged to achieve the consistent site 
of measurement, and a resolution box function was 
used to magnify this part of the artery. Three maximal 
IMT measurements of the far wall of the artery at 3 
mm intervals were obtained starting at 1 cm proximal 
to the bulb and moving proximally. The reported IMT 
for each side is the average of these 3 
measurements, and the reported IMT for each subject 
is the average of the 6 measurements (3 
measurements from the right and 3 from the left 
common carotid artery). Generally, images are 
recorded in the plane where the maximal cIMT can be 
visualised. Magnification of the vessel wall allows 
easy identification of the intimal-medial complex, 
defined by the border between the echolucent vessel 
lumen and the echogenic intima and the border 
between the echolucent media and echogenic 
adventitia. Image frames are selected based on areas 
where the intima-media complex is best visualised 
and appears the thickest, irrespective of the cardiac 
cycle, with manual assessment by the sonographer 
using electronic callipers online [19]. 
 
Renal Doppler 
Renal colour duplex ultrasound scans at 
baseline & after three years, using 3-6 MHz convex 
array transducer (Toshiba, Xario ultrasound machine). 
Patients were scanned in the supine position. The 
transducer was placed in a longitudinal position just to 
the Lt. of the midline, recording colour flow & Doppler 
spectrum from the abdominal aorta where peak 
systolic velocity of the abdominal aorta was recorded. 
Then, the transducer was placed in transverse 
position just distal to the origin of superior mesenteric 
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artery, to achieve transverse view of the aorta at the 
origins of both renal arteries where peak systolic 
velocity of both renal arteries was recorded, and renal 
artery stenosis was ruled out in all patients by tracing 
and examining different segments of both renal 
arteries from origin to renal hilum. Then, resistivity 
indices were recorded in the segmental, interlobar and 
arcuate arteries, on both sides 
 
Statistical Analysis 
Statistical analysis was conducted using 
Statistical Package for Social Science (SPSS) 
program version 17.0 (Chicago, Illinois, USA), t-test or 
Mann Whitney-U (for non-symmetrically distributed 
data) for independent variables was done. Chi-square 
was used for the analysis of NO genotype in both 
patients and controls. One-way ANOVA was used for 
comparing NO genotype about different other 
parameters followed by post HOCC test for detection 
of significance. 
 
 
Results 
 
Sixty-five type 1 diabetics (33 males and 32 
females) and 30 healthy volunteers (15 males and 15 
females) were in rolled in the study. The mean age of 
patients was 16.3 ± 1.5 yrs and mean duration of 
diabetes were 9.4 ± 2.9 yrs. HbA1c, 
albumin/creatinine ratio, cholesterol, triglyceride, LDL, 
OxLDL, cIMT and resistivity index were significantly 
higher, on the contrary, serum level of nitric oxide was 
significantly lower in diabetic patients (Table 1).  
Table 1: Comparison between demographics, laboratory data, 
carotid intimal medial thickness and resistivity index of 
diabetic patients and controls 
Variables 
Patients Controls 
P-value Mean SD Mean SD 
Age (yrs) 16.32 1.52 16.13 2.63 0.70 
Anthropometric data: 
     BMI (kg/m2) 24.91 4.20 24.76 5.67 0.8 
BMI (SDS) 24 
    Waist circumference (cm) 83.60 9.39 84.78 12.25 0.60 
HIP circumference (cm) 91.69 8.37 91.20 11.93 0.80 
Waist / hip ratio 0.91 0.06 0.93 0.05 0.20 
Waist / height ratio 0.51 0.06 0.52 0.08 0.90 
Blood pressure: 
     Systolic blood pressure 
(mmHg) 119.35 12.53 118.21 14.42 0.70 
Diastolic blood pressure 
(mmHg) 81.94 9.20 78.57 6.51 0.05 
Laboratory data: 
     HbA1 (%) 9.55 1.90 5.43 0.65 0.0001 
Albumin / creatinine ratio (µg/g 
creatinine) 
28.4 
78.33 ± 100.65 
(5.8 – 384.2) 
10.7 
11.28 ± 4.23 
(5.4 – 23.2) 0.0001# 
Total cholesterol (mg/dl) 188.81 63.77 100.54 20.41 0.0001 
Triglyceride (mg/dl) 103.46 78.29 68.89 28.39 0.03 
HDL-c (mg/dl) 51.77 20.58 52.21 11.12 0.90 
LDL-c (mg/dl) 118.66 47.53 62.50 19.88 0.0001 
Nitric oxide (µmol/l) 28.42 7.06 40.33 6.32 0.0001 
OxLDL (mg/l) 17.56 6.45 9.06 3.92 0.0001 
Image analysis: 
     Carotid intimal medial thickness 
(mm) 0.49 0.08 0.40 0.05 0.0001 
Resistivity index 0.60 0.04 0.5 0.01 0.004 
      t-test for independent variables; # Mann Whitney U test was used; Median, mean ± SD (range); 
BMI: body mass index; HbA1: glycosylated haemoglobin; LDL: Low-density lipoprotein; HDL: high-
density lipoprotein; OLDL: oxidised low-density lipoprotein. 
 
No significant difference was found in NO 
genotype in diabetic patients and controls (Table 2). 
Table 2: Comparison between nitric oxide genotype in diabetic 
patients and controls 
Genotype Patients Controls  P-value 
G894T: N % N %  
GG (normal) 39 62.9 15 53.6 0.7 
GT (hetero) 18 29 10 35.7  
TT (homo) 5 8.1 3 10.7  
GG: Normal genotype; GT: heterozygous genotype; TT: Homozygous genotype. 
 
Albumin/creatinine ratio, total cholesterol, 
triglyceride, LDL-c, OxLDL and nitric oxide revealed a 
significant difference with nitric oxide genotype. On 
the other hand, cIMT and resistivity index had no 
significant difference (Table 3 and Table 4). 
Table 3: Comparison between nitric oxide genotype and 
demographic, anthropometric, laboratory data and image study 
of diabetic patients included in the study 
Variables Normal (GG) 
(group 1) 
Hetero (GT) 
Group 2 
Homo (TT) 
Group 3 
P-value 
Mean SD Mean SD Mean SD  
Age (yr) 16.29 1.65 16.68 1.03 15.24 1.57 0.2 
Insulin dose 
(u/kg) 
1.40 0.47 1.49 0.44 1.42 0.32 0.80 
Waist/ hip ratio 0.91 0.07 0.93 0.06 0.88 0.04 0.30 
Waist / height 
ratio 
0.51 0.07 0.53 0.06 0.52 0.07 0.40 
BMI (kg/m
2
) 24.95 3.75 25.81 5.32 23.42 4.25 0.50 
HbA1c (%) 9.20 1.87 10.22 1.69 9.70 2.30 0.20 
Albumin / 
creatinine ratio 
(µg/g 
creatinine) 
52.32 72.41 109.86 116.81 174.06 159.05 0.01 
1 vs. 2,3 
Cholesterol 
(mg/dl) 
171.13 56.35 217.38 65.26 217.60 86.30 0.03 
1 vs 2,3 
Triglycerid 
(mg/dl) 
83.59 37.88 141.88 125.62 128.80 76.06 0.03 
1 vs 2 
HDL-c (mg/dl) 49.63 21.40 54.38 17.41 57.80 23.91 0.6 
 
LDL-c (mg/dl) 101.96 31.69 134.64 43.00 110.28 33.02 0.01 
1 vs 2 
Oxldl (ng/ml) 16.44 5.06 18.29 7.82 23.82 8.51 0.02 
1 vs 3 
Nitric oxide 31.28 5.49 25.13 6.67 17.88 4.19 0.0001 
1 vs. 2,3 
2 vs. 3 
Uric acid 
(mg/dl) 
4.63 0.75 4.60 0.74 4.70 0.52 0.90 
cIMT 0.50 0.07 0.47 0.09 0.47 0.07 0.4 
Resistivity index 0.60 0.04 0.60 0.03 0.60 0.04 0.80 
BMI: Body mass index; cIMT: carotid intimal medial thickness; LDL-c: low density 
lipoprotein cholesterol; HDL-c: High density lipoprotein cholesterol. 
 
 
Discussion 
 
In the current study, HbA1c, albumin / 
creatinine ratio, cholesterol, triglyceride LDL, OxLDL, 
cIMT and resistivity index were significantly higher 
while nitric oxide was significantly lower in diabetic 
patients.  
Type 1 diabetic patients in our study had 
significantly higher carotid artery IMT (cIMT) 
compared with normal control. These findings are in 
agreement with the findings of postmortem studies 
that have indicated a relation between early 
atherosclerotic lesions and diabetic state [20]. 
Järvisalo et al., [21], had reported that increased rate 
of subclinical atherosclerosis in a very young age is 
related to type 1 diabetes as a risk factor and it can be 
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detected by the presence of an increase in cIMT [21]. 
Several previous studies demonstrated that cIMT is 
increased in adults with type 1 diabetes [22], [23], 
[24], [25], [26], [27]. 
Table 4: Comparison between allele of nitric oxide genotype 
and demographic, anthropometric, laboratory data and image 
study of diabetic patients included in the study 
P-value Allele (GT or TT) Normal genotype 
(GG) 
Variables 
SD Mean SD Mean 
0.8 1.28 16.37 1.65 16.29 Age of patients (yrs) 
0.5 2.64 9.74 3.09 9.15 Duration of disease (yrs) 
0.5 0.41 1.47 0.47 1.40 Insulin dose (U/kg) 
0.2 15.26 116.52 10.46 121.03 Systolic blood pressure 
(mmHg) 
0.2 9.17 80.00 9.15 83.08 Diastolic blood pressure 
(mmHg) 
0.9 1.11 1.33 0.93 1.31 BMI (SDS) 
0.8 5.12 25.29 3.75 24.95 BMI (kg/m
2
) 
0.6 0.06 0.92 0.07 0.91 Waist/ hip ratio 
0.2 0.06 0.53 0.07 0.51 Waist/ height ratio 
0.06 1.79 10.11 1.87 9.20 HbA1c (%) 
0.006 126.38 124.45 72.41 52.32 Albumin/ creatinine ratio (µg/g 
creatinine) 
0.007 68.44 217.43 56.35 171.13 Cholesterol (mg/dl) 
0.008 114.12 138.76 37.88 83.59 Triglycerid (mg/dl) 
0.3 18.55 55.19 21.40 49.63 HDL (mg/dl) 
0.007 41.45 128.84 31.69 101.96 LDL (mg/dl) 
0.003 9.38 28.70 6.66 14.37 VLDL (mg/dl) 
0.07 8.13 19.55 5.06 16.44 Oxldl (mg/dl) 
0.0001 6.85 23.48 5.49 31.28 Nitric oxide 
0.7 9.78 4.10 1.01 3.91 Uric acid (mg/dl) 
0.2 0.08 0.47 0.07 0.50 cIMT (mm) 
0.5 0.03 0.60 0.04 0.60 Resistivity index (RI) 
BMI: Body mass index; CIMT: carotid intimal medial thickness; LDL-c: low-density 
lipoprotein cholesterol; HDL-c: High-density lipoprotein cholesterol. 
 
On the contrary, Singh et al., [19], reported 
that impairment in the endothelial function occurs in 
the first decade of the onset of type 1 diabetes, and 
after considerably longer exposure to the diabetic 
milieu the increase in cIMT occur. Our study revealed 
that diabetic children with impaired endothelial 
function also had increased cIMT. This discrepancy 
may be explained by differences in study populations 
and methodology. Additional genetic risk factors have 
been suggested to have the potential influence on 
atherosclerosis burden [19], but no supporting data 
exist. 
Our study revealed that diabetic patients had 
a significantly higher resistivity index (RI) (P = 0.004). 
Our results are comparable with results seen in type II 
diabetic patients [16], [19] and also comparable with 
the results of many previous studies in type I diabetic 
patients, which demonstrated that diabetic children 
with no clinical evidence of renal dysfunction have RI 
values significantly greater than in age-matched 
healthy controls; therefore, suggesting a preclinical 
stage of DN [28], [29], [30]. 
No significant difference was found between 
nitric oxide genotype of diabetic patients and controls 
in our study. On the contrary, in type 2 diabetes as 
compared to normal population NOS synthase gene 
polymorphism was more common, but no correlation 
was not found between this gene polymorphism and 
retinopathy or proteinuria [3]. 
In the present study, albumin / creatinine ratio 
was significantly higher in patients with heterozygous 
and homozygous nitric oxide genotype. An 
association between diabetic nephropathy and 3 
eNOS polymorphism (894G > T, 27-bp-VNTR and -
786T > C) was found in a study on 400 diabetic 
patients, [31]. In the Chinese population, and not in 
non-Asian populations Ze-jun Ma et al., in a meta-
analysis, found a significant association between 
diabetic nephropathy and the eNOS-4b / a 
polymorphism [32)]. Khamaisi showed that at the 
progressive phase of diabetes decreasing renal NOS 
activity is accompanied by a decline in neuronal NOS 
activity and protein expression [33]. Rippin et al., [34] 
and Momeni et al., [3], found no correlation between 
diabetic nephropathy and NOs polymorphism in their 
study done on type 1 diabetic patients. El-Din and 
Hamdy [35], reported that risk of end-stage renal 
disease in type 2 diabetic patients was associated 
with TT genotype of eNOS, so it may be a useful 
marker to identify diabetic patients with high risk. In a 
systemic review, the association of DN with eNOS T-
786C gene polymorphism and 4b / a gene 
polymorphism was reported by Dellamea et al., [36]. 
While Bernhard et al., concluded that eNOS gene 
polymorphism doesn’t play a significant role in the 
development of diabetic nephropathy in their study on 
either type 1 or type 2 diabetic patients [37]. 
eNOS gene polymorphisms that lead to 
decreased NO expression have been implicated with 
DN. The mechanism responsible for the potential 
association between risk of DN and eNOS 
polymorphisms is not known yet. However, variants of 
the eNOS gene may cause defective NO synthesis 
and decreased NO levels, which enhance the 
susceptibility to glomerular disease and deteriorate 
the renal function [38]. 
Cholesterol, triglyceride, LDL, OxLDL were 
significantly higher, while nitric oxide was significantly 
lower in nitric oxide genotype polymorphism 
(heterozygous or homozygous). In a study by 
Corapciogluin on 102 controls and 97 Turkish diabetic 
foot ulcer patients, it was reported that eNOS G894T 
polymorphism, GT-TT alleles were significantly higher 
than the GG alleles in patients with atherosclerotic 
heart disease [39]. 
It has been shown that atherosclerosis in 
animal models is accelerated by eNOS inhibition and 
that endothelial NO pathway abnormalities are 
present in humans with atherosclerosis [40]. This 
evidence suggests that several key steps may be 
inhibited by NO in the atherosclerotic process and that 
an alteration of NO production within the vascular 
endothelium could contribute to the pathogenesis of 
atherosclerosis. Thus, eNOS could be a candidate 
gene for atherosclerosis [41]. In human endothelial 
nitric oxide synthase (eNOS) gene, a single base 
exchange (G894 →T) in exon 7 results in a Glu → 
Asp substitution at residue 298 of the eNOS gene 
[42]. 
Limitation of the study is the number of 
patients small, and from our knowledge, no 
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researches are done in type 1 diabetes in this topic 
before. 
We conclude that diabetic patients are liable 
for the occurrence of early diabetic nephropathy and 
atherosclerosis as a result of the presence of low level 
of nitric oxide. Nitric oxide gene polymorphism in 
diabetic patients is a risk factor for diabetic 
nephropathy and atherosclerosis. 
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